drugset / Trial / NCT05909709
Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to see if the use of Alocyte (cord blood plasma plus mononucleic cells) will be safe, well tolerated, and whether it causes any side effects. The study will also examine if the use of the Investigational Product (IP) is able to reduce local inflammation or alleviate Facetogenic back pain
Timeline
- Start
- 2024-04-29
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alocyte | Cell therapy | 2 ml | Other |
| Subject | Alocyte | Cell therapy | 6 ml | Other |
| Subject | Alocyte | Cell therapy | 10 ml | Other |